Search

Ramtace

Ramtace

ramipril

Manufacturer:

Y.S.P. Industries

Distributor:

Y.S.P. Industries
Concise Prescribing Info
Contents
Ramipril
Indications/Uses
HTN, CHF. Patients whom w/in 1st few days after an acute MI have demonstrated clinical signs of CHF. Risk reduction of MI, stroke or CV death & need for revascularization procedures in patients ≥55 yr. Progressive renal failure in patients w/ persistent proteinuria.
Click to view Ramtace detailed prescribing information
Dosage/Direction for Use
HTN Initially 2.5 mg once daily, may be doubled at 2-3 wk interval depending on the patient's response. Usual maintenance dose: 2.5-5 mg daily. Max: 10 mg daily. CHF Initially 1.25 mg once daily, may be doubled at 1-2 wk interval depending on the patient's response. Max: 10 mg daily. MI Initially, 5 mg daily in 2 divided doses (morning & evening), may be reduced to 1.25 mg bd for 2 days if not well tolerated. Dose increased may be doubled at 1-3 day interval depending on the patient's response. Max: 10 mg daily. Severe heart failure after MI Initially 1.25 mg once daily. Prevention of progressive renal failure in patient w/ persistent proteinuria Initially 1.25 mg once daily, may be doubled at 2-3 wk interval depending on the patient's response. Patient at increased CV risk Initially 2.5 mg once daily, may be doubled after 1 wk & may be increased to 10 mg after 3 wk. Usual maintenance dose: 10 mg daily. Elderly, patient w/ uncorrected fluid or salt deficiency, severe HTN, haemodynamically relevant coronary arteries or blood vessels stenoses, patient pre-treated w/ diuretic Initially 1.25 mg daily. CrCl 20-50 mL/min/1.73 m2 Initially 1.25 mg daily. Max: 5 mg daily. Hepatic impairment Max: 2.5 mg daily.
Click to view Ramtace detailed prescribing information
Overdosage
View Ramtace overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food: Swallow whole w/ liqd, do not chew/crush.
Contraindications
Hypersensitivity to ramipril & other ACE inhibitors. History of angioedema. Extracorporeal treatments leading to contact of blood w/ negatively charged surfaces, significant bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney, hypotensive or haemodynamically unstable states. 2nd & 3rd trimesters of pregnancy.
Click to view Ramtace detailed prescribing information
Warnings
For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Ramtace detailed prescribing information
Special Precautions
Hypotension, strongly activated renin-angiotensin-aldosterone system, severe HTN, decompensated CHF, aortic or mitral valve stenosis, unilateral renal artery stenosis w/ 2nd functional kidney, fluid or salt depletion, liver cirrhosis &/or ascites, undergoing major surgery or during anaesth w/ agents producing hypotension, transient or persistent heart failure post MI, cardiac or cerebral ischemia in case of acute hypotension. Assess renal function before & during treatment. Discontinue use prior to desensitization. Regularly monitor serum K, WBC count. Renal insufficiency, uncontrolled DM, dehydration, acute cardiac decompensation, metabolic acidosis. Cough. Black patients. Concomitant use w/ K salts, K-retaining diuretics. May impair ability to drive & use machines. Not recommended in 1st trimester of pregnancy & lactation. Childn & adolescents <18 yr. Elderly >70 yr.
Click to view Ramtace detailed prescribing information
Adverse Reactions
Persistent dry cough & reactions due to hypotension. Angioedema, hyperkalaemia, renal or hepatic impairment, pancreatitis, severe skin reactions & neutropenia/agranulocytosis. Myocardial ischaemia; eosinophilia, other blood & lymphatic disorders; headache, dizziness, vertigo, paraesthesia, ageusia, dysgeusia, tremor, balance disorder, cerebral ischaemia; visual disturbance; impaired hearing, tinnitus; other resp disorders; GI disorders; muscle spasms, myalgia, arthralgia; increased blood K & Na, anorexia, decreased appetite; chest pain, fatigue, pyrexia, asthenia; immune & reproductive system & psychiatric disorders.
Drug Interactions
Increased risk of severe anaphylactoid reaction w/ dialysis or haemofiltration w/ certain high-flux membranes & LDL apheresis w/ dextran sulphate. Hyperkalaemia w/ K salts, heparin, K-retaining diuretics, AIIA, trimethoprim, tacrolimus, ciclosporin. Potentiated risk of hypotension w/ antihypertensives & other substances decreasing BP (eg, nitrates, TCAs, anesth, acute alcohol intake, baclofen, alfuzosin, doxazosin, prazosin, tamsulosin, terazosin). Reduced antihypertensive effect w/ vasopressor sympathomimetics, isoproterenol, dobutamine, dopamine, epinephrine. Increased likelihood of haematological reactions w/ allopurinol, immunosuppressants, corticosteroids, procainamide, cytostatics & other substances affecting blood cell count. Increased lithium toxicity. Hypoglycaemic reactions w/ antidiabetic agents (ie, insulin). Reduced antihypertensive effect, increased risk of renal function worsening & increased kalaemia w/ NSAIDs & ASA.
Click to view Ramtace detailed prescribing information
Storage
View Ramtace storage conditions for details to ensure optimal shelf-life.
Description
View Ramtace description for details of the chemical structure and excipients (inactive components).
Action
View Ramtace mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
ACE Inhibitors/Direct Renin Inhibitors
ATC Classification
C09AA05 - ramipril ; Belongs to the class of ACE inhibitors. Used in the treatment of cardiovascular disease.
Presentation/Packing
Form
Ramtace tab 10 mg
Packing/Price
10 × 10's;3 × 10's
Form
Ramtace tab 5 mg
Packing/Price
10 × 10's;3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in